Infant Exposure to MS Drugs via Breastfeeding: New Data
Infant exposure to monoclonal antibodies used to treat MS via breast milk does not negatively affect health or development out to 3 years, a new study shows.
Source: medscape.com
Kerstin Hellwig News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Kerstin Hellwig. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Kerstin Hellwig Today - Breaking & Trending Today
Breastfeeding While Taking MS Monoclonal Antibody Drugs Appears Safe
No negative effects on early infant development or health seen
Source: medpagetoday.com
Less Frequent Dosing With MS Drug Safe With No Loss of Efficacy
Patients with MS stable on natalizumab administered every 4 weeks may be able to safely switch to every-6-weeks dosing with no clinically meaningful loss of efficacy.
Source: medscape.com
COPAXONE® label updated to help breastfeeding mothers with relapsing MS
Teva Pharmaceuticals Europe BV has confirmed that the SmPC for COPAXONE® (Glatiramer Acetate (GA) injection) 20mg/mL and 40mg/mL, indicated for the treatment of relapsing forms of multiple sclerosis (RMS) in Europe, has been updated.
Source: europeanpharmaceuticalreview.com
Teva Pharmaceutical Industries Limited: COPAXONE Label Now Indicates Its Use in Breastfeeding Mothers with Relapsing Multiple Sclerosis
Change to COPAXONE(Glatiramer Acetate (GA)) Summary of Product Characteristics (SmPC) in breastfeeding is relevant for the Multiple Sclerosis ("MS") community and provides information for neurologists
Source: finanznachrichten.de